Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX

Wealth Enhancement Advisory Services LLC grew its position in Royalty Pharma PLC (NASDAQ:RPRX) by 701.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 189,046 shares of the biopharmaceutical company’s stock after purchasing an additional 165,451 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Royalty Pharma were worth $7,685,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. CWM LLC lifted its holdings in Royalty Pharma by 1.5% during the 3rd quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 281 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Royalty Pharma by 9.6% during the third quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 289 shares in the last quarter. Hudson Bay Capital Management LP increased its holdings in shares of Royalty Pharma by 1.0% during the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 289 shares in the last quarter. Merit Financial Group LLC raised its stake in shares of Royalty Pharma by 3.5% in the third quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock valued at $323,000 after acquiring an additional 306 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Down 1.3%

RPRX stock opened at $46.35 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $47.86. The company has a market cap of $26.74 billion, a P/E ratio of 34.33 and a beta of 0.40. The business has a fifty day moving average of $44.42 and a 200-day moving average of $40.23.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. As a group, equities research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.0%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s payout ratio is presently 69.63%.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 16th. The shares were sold at an average price of $39.52, for a total transaction of $790,400.00. Following the completion of the sale, the executive vice president owned 40,000 shares of the company’s stock, valued at approximately $1,580,800. The trade was a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Terrance P. Coyne sold 114,954 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the sale, the chief financial officer owned 23,972 shares of the company’s stock, valued at $1,026,960.48. The trade was a 82.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 532,287 shares of company stock worth $22,215,917 over the last 90 days. 18.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on RPRX shares. Leerink Partners set a $45.00 price target on Royalty Pharma in a report on Thursday, December 11th. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a report on Friday, January 30th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $61.00 price target on shares of Royalty Pharma in a research report on Thursday, February 12th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $48.67.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.